Clinical trials: High-risk Myelodysplastic Syndromes

Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

• Terminated
• Age: 18 years and older
• Phase 2

This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are naïve, to…

Trial name

NCT02147873

Testing

birinapant, Azacitidine

Where

76 sites in United States, Australia and 2 more

Volunteers

118 people

Sponsor

TetraLogic Pharmaceuticals